Prostate specific genes and the use thereof as targets for prostate cancer therapy
First Claim
Patent Images
1. An isolated nucleic acid sequence that is expressed by human prostate cancer cells, selected from the group consisting of:
- (i) the nucleic acid sequence contained in SEQ ID NOS.;
1 to 173, 175, 177, 179, 181;
(ii) variants thereof, wherein such variants have a nucleic acid sequence that is at least 70% identical to the sequence of (i) when aligned without allowing for gaps; and
(iii) fragments of (i) or (ii) having a size of at least 20 nucleotides in length.
1 Assignment
0 Petitions
Accused Products
Abstract
Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer.
-
Citations
34 Claims
-
1. An isolated nucleic acid sequence that is expressed by human prostate cancer cells, selected from the group consisting of:
-
(i) the nucleic acid sequence contained in SEQ ID NOS.;
1 to 173, 175, 177, 179, 181;
(ii) variants thereof, wherein such variants have a nucleic acid sequence that is at least 70% identical to the sequence of (i) when aligned without allowing for gaps; and
(iii) fragments of (i) or (ii) having a size of at least 20 nucleotides in length. - View Dependent Claims (2, 3, 16, 17)
-
-
4. A method of detecting prostate cancer comprising determining whether a human prostate cell sample expresses a target nucleic acid molecule, wherein said target nucleic acid molecule comprises the sequence of a gene or RNA comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOS.:
- 1 to 173, 175, 177, 179, 181 or of a fragment of said gene or RNA having a size of at least 20 nucleotides in length.
- View Dependent Claims (5, 6, 7, 8, 9)
-
10. An antigen expressed by human prostate cancer cells, wherein said antigen is selected from the group consisting of:
-
(i) the antigen encoded by a nucleic acid sequence having at least 90% sequence identity in SEQ ID NOS.;
1 to 173, 175, 177, 179, 181;
(ii) an antigen derived from a protein comprising a sequences having at least 90% identity in SEQ ID NOS. 174, 176, 178, 180, 182-185; and
(iii) an antigenic fragment of (i) or (ii). - View Dependent Claims (12, 14, 15, 18, 23)
-
-
11. A prostate antigen comprising (i) the amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs.:
- 1 to 173, 175, 177, 179, 181 or (ii) an amino acid sequence selected from SEQ ID NOS.;
174, 176, 178, 180, and 182-185, or (iii)an antigenic fragment of (i) or (ii). - View Dependent Claims (13)
- 1 to 173, 175, 177, 179, 181 or (ii) an amino acid sequence selected from SEQ ID NOS.;
-
19. A method for treating prostate cancer, which comprises administering to a subject a therapeutically effective amount of a ligand which specifically binds a target molecule selected from (i) a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.:
- 1 to 173, 175, 177, 179, 181, a variant thereof or a fragment of said gene or RNA having a size of at least 20 nucleotides in length, and (ii) a protein or polypeptide encoded by a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.;
1 to 173, 175, 177, 179, 181, a variant thereof or a fragment of said gene or RNA having a size of at least 20 nucleotides in length, or a polypeptide derived from SEQ ID NOS.;
174, 176, 178, 180, and 182-185. - View Dependent Claims (20, 21, 22)
- 1 to 173, 175, 177, 179, 181, a variant thereof or a fragment of said gene or RNA having a size of at least 20 nucleotides in length, and (ii) a protein or polypeptide encoded by a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.;
-
24. A method for treating prostate cancer comprising administering to a subject a therapeutically effective amount of a ligand which specifically binds to a protein encoded by a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.:
- 1 to 173, 175, 177, 179, 181 or a fragment, or variant thereof, or a polypeptide derived from SEQ ID NOS.;
174, 176, 178, 180, and 182-185 optionally directly or indirectly attached to a therapeutic effector moiety. - View Dependent Claims (25, 26, 27, 28, 29, 30, 31)
- 1 to 173, 175, 177, 179, 181 or a fragment, or variant thereof, or a polypeptide derived from SEQ ID NOS.;
-
32. A molecule, selected from:
-
(i) a polypeptide comprising the sequence of an extracellular domain of a protein encoded by a gene or RNA comprising a sequence selected from the group consisting of SEQ ID NOS.;
1 to 185; and
(ii) a nucleic acid molecule encoding a polypeptide of (i). - View Dependent Claims (33)
-
-
34. A method for selecting, identifying, screening, characterizing or optimizing biologically active compounds, comprising contacting a candidate compound with a target molecule and determining whether the candidate compound binds said target molecule, wherein said target molecule is selected from (i) a nucleic acid molecule comprising the sequence of a gene or RNA comprising a nucleic acid sequence selected from the group consisting of SEQ ID NOS.:
- 1 to 173, 175, 177, 179, 181, (ii) a fragment of said gene or RNA having a size of at least 20 nucleotides in length, and (iii) a polypeptide encoded by (i) or (ii) or a polypeptide derived from SEQ ID NOs.;
174, 176, 178, 180, and 182-185.
- 1 to 173, 175, 177, 179, 181, (ii) a fragment of said gene or RNA having a size of at least 20 nucleotides in length, and (iii) a polypeptide encoded by (i) or (ii) or a polypeptide derived from SEQ ID NOs.;
Specification